NORCO, Calif. & COLUMBUS, Ohio--(BUSINESS WIRE)--Destroy Duchenne, a nonprofit organization founded by DMD patient, Elijah Stacy that aims to Complete the Cure TM for Duchenne Muscular Dystrophy (DMD) ...
Dyno to receive a $15 million fee plus potential milestone and royalty payments under terms established in the companies' 2021 research collaboration. This marks Dyno’s second capsid licensed from its ...
Dyne Therapeutics’ experimental treatment for Duchenne muscular dystrophy (DMD) showed promise in new data from a small Phase 1/2 trial dubbed DELIVER, the pharma announced this week. The drug, ...
Dyne Therapeutics Inc (NASDAQ:DYN) released initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its DELIVER trial of DYNE-251 in patients with ...
Mammoth Biosciences researchers have developed NanoCas, an ultracompact CRISPR nuclease, demonstrating its ability to perform gene editing in non-liver tissues, including skeletal muscle, using a ...
- All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101 Q4W Demonstrated Consistent Splicing Correction with a 19% Mean Improvement Across 22-Gene Panel at 3 Months - - Improvement in ...
New York, Aug. 23, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and Parent Project Muscular Dystrophy (PPMD) today announced the publication of jointly developed consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results